Key Points
- Director Morgan Lee Lekstrom purchased 23,500 shares on February 3 at $3.06 each for $71,910, bringing his direct ownership to 102,500 shares — a 29.75% increase.
- Lekstrom has been buying heavily in late January–early February, acquiring a total of 95,500 shares across five trades for roughly $302,550.
- STEX recently traded near $3.32 (one‑year range $0.40–$14.11) and carries an average analyst rating of "Sell", including coverage from Weiss Ratings.
Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) Director Morgan Lee Lekstrom bought 23,500 shares of the company's stock in a transaction dated Tuesday, February 3rd. The stock was bought at an average price of $3.06 per share, for a total transaction of $71,910.00. Following the acquisition, the director directly owned 102,500 shares of the company's stock, valued at approximately $313,650. This represents a 29.75% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Morgan Lee Lekstrom also recently made the following trade(s):
- On Thursday, January 29th, Morgan Lee Lekstrom purchased 2,500 shares of Biosig Technologies stock. The shares were bought at an average price of $3.70 per share, with a total value of $9,250.00.
- On Monday, January 26th, Morgan Lee Lekstrom purchased 23,000 shares of Biosig Technologies stock. The stock was bought at an average cost of $3.30 per share, with a total value of $75,900.00.
- On Tuesday, January 27th, Morgan Lee Lekstrom acquired 5,500 shares of Biosig Technologies stock. The shares were bought at an average price of $3.12 per share, for a total transaction of $17,160.00.
- On Friday, January 23rd, Morgan Lee Lekstrom acquired 41,000 shares of Biosig Technologies stock. The shares were purchased at an average cost of $3.13 per share, for a total transaction of $128,330.00.
Biosig Technologies Trading Down 0.3%
Shares of STEX stock opened at $3.32 on Wednesday. Biosig Technologies, Inc. has a one year low of $0.40 and a one year high of $14.11.
Analysts Set New Price Targets
Separately, Weiss Ratings started coverage on shares of Biosig Technologies in a research report on Friday, January 23rd. They set a "sell (d-)" rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of "Sell".
Check Out Our Latest Research Report on STEX
Biosig Technologies Company Profile
(
Get Free Report)
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
